Multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of 2 SENS-111 dosage regimens (100mg and 200mg) administered orally for 4 days in patients suffering from acute unilateral vestibulopathy.
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: 4SENSORION
- Phase: II
- Execution start: 17/09/2018
- End of execution: 30/09/2019
- IP: JOSE ANTONIO LOPEZ ESCAMEZ